Clinical and Applied Thrombosis/Hemostasis最新文献_第5页

Anti-Xa Monitoring of Apixaban (ZyQuis) in Venous Thrombo-Embolism and Atrial Fibrillation 阿哌沙班（ZyQuis）在静脉血栓栓塞和心房颤动中的抗 Xa 监测

IF 2.9 4区医学

Clinical and Applied Thrombosis/Hemostasis Pub Date : 2024-04-25 DOI: 10.1177/10760296241249167

Elise Schapkaitz, Byron Ter Morshuizen, Melanie Mc Cree, Barry F. Jacobson

{"title":"Anti-Xa Monitoring of Apixaban (ZyQuis) in Venous Thrombo-Embolism and Atrial Fibrillation","authors":"Elise Schapkaitz, Byron Ter Morshuizen, Melanie Mc Cree, Barry F. Jacobson","doi":"10.1177/10760296241249167","DOIUrl":"https://doi.org/10.1177/10760296241249167","url":null,"abstract":"Apixaban is a direct oral Xa inhibitor and is indicated for the treatment of venous thrombo-embolism (VTE) and prevention of stroke in atrial fibrillation (AF). Recently, a generic (ZyQuis, Zydus Lifesciences Limited, India) has received Food and Drug Administration approval. While bioequivalence has been demonstrated with Eliquis (Bristol-Myers Squibb/Pfizer, UK), it is necessary to monitor its effectiveness prior to acceptance in medical practice. This prospective study independently evaluated Apixaban (ZyQuis) at two accredited laboratories. Participants were converted from Warfarin or Rivaroxaban to Apixaban 5 mg bd for a duration of one month. Peak anti-Xa levels were measured 3-4 h post the morning dose. The samples were processed on the Atellica COAG 360 (Siemens Healthineers, Marburg, Germany) analyzers with a chromogenic anti-Xa assay (Innovance, reference interval 69-321 ng/mL). There were 26 participants; 5 men, 21 women; mean ± standard deviation age of 46 ± 12 years. Indications for anticoagulation included: VTE (88.5%) and AF (11.5%). 69.2% of the participants had at least one comorbidity. 96.2% of the anti-Xa levels were within the laboratory's 95% reference interval. Mean anti-Xa activity was 191 ± 69 ng/mL and 186 ± 68 ng/mL measured at respective laboratories. Mean differences in anti-Xa measurements represented by Bland–Altman statistics were small (bias of −2.6%, 95% confidence interval −1.11 to −4.09) and a strong correlation was observed on Deming regression analysis (0.995). Apixaban (ZyQuis) was effective for the management of VTE and AF as evidenced by anti-Xa activity.","PeriodicalId":10335,"journal":{"name":"Clinical and Applied Thrombosis/Hemostasis","volume":"266 1","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140803233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Challenges to Laboratory Monitoring of Direct Oral Anticoagulants 实验室监测直接口服抗凝药面临的挑战

IF 2.9 4区医学

Clinical and Applied Thrombosis/Hemostasis Pub Date : 2024-04-23 DOI: 10.1177/10760296241241524

Jesse Qiao, Minh-Ha Tran

{"title":"Challenges to Laboratory Monitoring of Direct Oral Anticoagulants","authors":"Jesse Qiao, Minh-Ha Tran","doi":"10.1177/10760296241241524","DOIUrl":"https://doi.org/10.1177/10760296241241524","url":null,"abstract":"Direct oral anticoagulants (DOACs) exert anticoagulation effect by directly inhibiting Factor Xa (rivaroxaban, apixaban, and edoxaban) or thrombin (dabigatran). Though DOACs are characterized by fixed-dose prescribing and generally do not require routine laboratory drug-level monitoring (DLM), circumstances may arise where the DLM may aid in clinical decision-making, including DOAC dose adjustment, anticoagulant class change, or decisions to withhold or administer reversal agents. We review the current literature that describes high-risk patient groups in which DLM may be beneficial for improved patient anticoagulation management and stewardship. The review also summarizes the limitations of conventional coagulation testing and discuss the emerging utility of quantitative methods for routine and rapid emergent evaluation of DOAC drug levels—in particular, the Anti-Xa activity to detect Factor Xa Inhibitors (rivaroxaban, apixaban, and edoxaban). Both technical and regulatory barriers to widespread DLM implementation are limiting factors to further clinical research that must be overcome, in order to propose universal DOAC DLM strategies and provide clinical-laboratory correlation to formally classify high-risk patient groups.","PeriodicalId":10335,"journal":{"name":"Clinical and Applied Thrombosis/Hemostasis","volume":"12 1","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140803227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Relationship of Coronary Thrombus Burden and Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Score in Patients With ST-Segment Elevation Myocardial Infarction ST段抬高型心肌梗死患者冠状动脉血栓负担与抗凝及心房颤动危险因素（ATRIA）评分的关系

IF 2.9 4区医学

Clinical and Applied Thrombosis/Hemostasis Pub Date : 2024-04-22 DOI: 10.1177/10760296241237232

Gökhan Coşkun, Cem Ozde, Osman Kayapinar, Gulsah Aktore, Ensar Ekşi, Hamdi Afşin, Ahmet Egemen Sayın

{"title":"The Relationship of Coronary Thrombus Burden and Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Score in Patients With ST-Segment Elevation Myocardial Infarction","authors":"Gökhan Coşkun, Cem Ozde, Osman Kayapinar, Gulsah Aktore, Ensar Ekşi, Hamdi Afşin, Ahmet Egemen Sayın","doi":"10.1177/10760296241237232","DOIUrl":"https://doi.org/10.1177/10760296241237232","url":null,"abstract":"BackgroundThe anticoagulation and risk factors in atrial fibrillation (ATRIA) score is associated with adverse cardiovascular events. However, its relationship with coronary thrombus burden is unclear. Therefore, we aimed to investigate the relationship between the ATRIA score and thrombus burden in patients with ST-segment elevation myocardial infarction (STEMI) who underwent percutaneous coronary intervention (PCI).Materials and MethodsThe study was designed as a prospective cross-sectional observational study. Our study included 319 patients who were prospectively admitted with STEMI between January 2021 and April 2022. Patients were divided into 2 groups with low thrombus burden (LTB) (grade <3) and high thrombus burden (HTB) (grade ≥3). ATRIA score was calculated and recorded for all patients. ATRIA scores of both groups were compared.ResultsIn our study, 58.9% ( n = 188) of patients in the LTB group and 41% ( n = 131) of patients in the HTB group. The ATRIA risk score ( p < .001) was significantly higher in the HTB group. In multivariate logistic regression analysis, ATRIA score, glomerular filtration rate, hypertensıon, abciximab usage, and no-reflow were found to be independent predictors of HTB in STEMI patients undergoing primary PCI. In receiver operating characteristic analysis, ATRIA score >4 had a sensitivity of 66.2% and specificity of 95.2%, and ATRIA score >8 sensitivity of 98% and specificity of 100% predicted HTB.ConclusionIn this study, we found that thrombus burden may be associated with ATRIA risk score in patients presenting with STEMI.","PeriodicalId":10335,"journal":{"name":"Clinical and Applied Thrombosis/Hemostasis","volume":"19 1","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140803228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Venous Thromboembolism Risk Factors in Women With Obesity Who Undergo Cesarean Delivery 剖腹产肥胖妇女的静脉血栓栓塞风险因素

IF 2.9 4区医学

Clinical and Applied Thrombosis/Hemostasis Pub Date : 2024-04-15 DOI: 10.1177/10760296241247203

Tolulope B. Fatokun, Sarah E. Swartz, Ahmed Ebeid, Sophia A. Cordes, Alexis C. Gimovsky, Andrew D. Sparks, Richard L. Amdur, Homa K. Ahmadzia

{"title":"Venous Thromboembolism Risk Factors in Women With Obesity Who Undergo Cesarean Delivery","authors":"Tolulope B. Fatokun, Sarah E. Swartz, Ahmed Ebeid, Sophia A. Cordes, Alexis C. Gimovsky, Andrew D. Sparks, Richard L. Amdur, Homa K. Ahmadzia","doi":"10.1177/10760296241247203","DOIUrl":"https://doi.org/10.1177/10760296241247203","url":null,"abstract":"Venous thromboembolism (VTE) is a leading cause of maternal mortality. Obesity and cesarean delivery are established risk factors for pregnancy-related VTE. We identified additional risk factors among patients with obesity who underwent a cesarean delivery to identify those who need VTE prophylaxis. We conducted a secondary analysis of data from the Maternal-Fetal Medicine Units Network (MFMU) Cesarean Registry Database using a case-control design. Cases were identified as women with obesity having a pre-pregnancy body mass index of >30 kg/m2, who underwent cesarean delivery and subsequently developed deep venous thrombosis (DVT) or pulmonary embolism (PE). These women were compared to a control group of women with obesity who underwent cesarean delivery but did not develop DVT or PE. Analysis of risk factors associated with VTE was performed using Chi-Square test and Fisher's exact test. We identified 43 VTE cases and 172 controls in the MFMU database. Increased risk of VTE was noted in women with endometritis (OR of 4.58 [95% CI: 1.86-11.2, P = .0004]), receiving a blood transfusion (OR 17.07 [95% CI: 4.46-65.3, P = .0001]), having a coagulopathy (OR 27.73 [95% CI: 3.24-237.25, P = .0003]), and urinary tract infection (OR 2.39 [95% CI: 1.08-5.28, P = .03]). Important risk factors for VTE in women with obesity who undergo cesarean delivery include endometritis, intra- or post-operative transfusion, coagulopathy, and urinary tract infection. The presence of one or more of these factors may help guide provider decision-making regarding whether to administer thromboprophylaxis.","PeriodicalId":10335,"journal":{"name":"Clinical and Applied Thrombosis/Hemostasis","volume":"102 1","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140590019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk Factors Associated With Exclusion of Obese Patients Ischemic Stroke With a History of Smoking From Thrombolysis Therapy 将有吸烟史的肥胖缺血性脑卒中患者排除在溶栓治疗之外的相关风险因素

IF 2.9 4区医学

Clinical and Applied Thrombosis/Hemostasis Pub Date : 2024-04-11 DOI: 10.1177/10760296241246264

Philip C. Brewer, Dami T. Ojo, Philip X. Broughton, Adebobola Imeh-Nathaniel, Samuel Imeh-Nathaniel, Thomas I. Nathaniel

{"title":"Risk Factors Associated With Exclusion of Obese Patients Ischemic Stroke With a History of Smoking From Thrombolysis Therapy","authors":"Philip C. Brewer, Dami T. Ojo, Philip X. Broughton, Adebobola Imeh-Nathaniel, Samuel Imeh-Nathaniel, Thomas I. Nathaniel","doi":"10.1177/10760296241246264","DOIUrl":"https://doi.org/10.1177/10760296241246264","url":null,"abstract":"The objective of this study is to determine risk factors that may contribute to exclusion decision from recombinant tissue plasminogen activator (rtPA) in patients with acute ischemic stroke (AIS) with a combined current or history of smoking and obesity. This study was conducted on data from 5469 patients with AIS collected from a regional stroke registry. Risk factors associated with inclusion or exclusion from rtPA were determined using multivariate logistic regression analysis. The adjusted odds ratios and 95% confidence interval for each risk factor were used to predict the increasing odds of an association of a specific risk factor with exclusion from rtPA. In the adjusted analysis, obese patients with AIS with a history of smoking (current and previous) excluded from rtPA were more likely to present with carotid artery stenosis (OR = 0.069, 95% CI 0.011-0.442), diabetes (OR = 0.604, 95% CI 0.366-0.997), higher total cholesterol (OR = 0.975, 95% CI 0.956-0.995), and history of alcohol use (OR = 0.438, 95% CI 0.232-0.828). Higher NIHSS score (OR = 1.051, 95% CI 1.017-1.086), higher triglycerides (OR = 1.004, 95% CI 1.001-1.006), and higher high-density lipoprotein (OR = 1.028, 95% CI 1.000-1.057) were associated with the inclusion for rtPA. Our findings reveal specific risk factors that contribute to the exclusion of patients with AIS with a combined effect of smoking and obesity from rtPA. These findings suggest the need to develop management strategies to improve the use of rtPA for obese patients with AIS with a history of smoking.","PeriodicalId":10335,"journal":{"name":"Clinical and Applied Thrombosis/Hemostasis","volume":"35 1","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140590122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Detection of a Prethrombotic State in Patients with Hepatocellular Carcinoma, Using a Clot Waveform Analysis 利用凝血波形分析检测肝细胞癌患者的血栓前状态

IF 2.9 4区医学

Clinical and Applied Thrombosis/Hemostasis Pub Date : 2024-04-09 DOI: 10.1177/10760296241246002

Shunsuke Fukui, Hideo Wada, Kohei Ikeda, Mayu Kobayashi, Yasuaki Shimada, Yuuichi Nakazawa, Hiroki Mizutani, Yuhuko Ichikawa, Yuuki Nishiura, Isao Moritani, Yutaka Yamanaka, Hidekazu Inoue, Motomu Shimaoka, Hideto Shimpo, Katsuya Shiraki

{"title":"Detection of a Prethrombotic State in Patients with Hepatocellular Carcinoma, Using a Clot Waveform Analysis","authors":"Shunsuke Fukui, Hideo Wada, Kohei Ikeda, Mayu Kobayashi, Yasuaki Shimada, Yuuichi Nakazawa, Hiroki Mizutani, Yuhuko Ichikawa, Yuuki Nishiura, Isao Moritani, Yutaka Yamanaka, Hidekazu Inoue, Motomu Shimaoka, Hideto Shimpo, Katsuya Shiraki","doi":"10.1177/10760296241246002","DOIUrl":"https://doi.org/10.1177/10760296241246002","url":null,"abstract":"Background: Although hepatocellular carcinoma (HCC) is frequently associated with thrombosis, it is also associated with liver cirrhosis (LC) which causes hemostatic abnormalities. Therefore, hemostatic abnormalities in patients with HCC were examined using a clot waveform analysis (CWA). Methods: Hemostatic abnormalities in 88 samples from HCC patients, 48 samples from LC patients and 153 samples from patients with chronic liver diseases (CH) were examined using a CWA-activated partial thromboplastin time (APTT) and small amount of tissue factor induced FIX activation (sTF/FIXa) assay. Results: There were no significant differences in the peak time on CWA-APTT among HCC, LC, and CH, and the peak heights of CWA-APTT were significantly higher in HCC and CH than in HVs and LC. The peak heights of the CWA-sTF/FIXa were significantly higher in HCC than in LC. The peak times of the CWA-APTT were significantly longer in stages B, C, and D than in stage A or cases of response. In the receiver operating characteristic (ROC) curve, the fibrin formation height (FFH) of the CWA-APTT and CWA-sTF/FIXa showed the highest diagnostic ability for HCC and LC, respectively. Thrombosis was observed in 13 HCC patients, and arterial thrombosis and portal vein thrombosis were frequently associated with HCC without LC and HCC with LC, respectively. In ROC, the peak time×peak height of the first derivative on the CWA-sTF/FIXa showed the highest diagnostic ability for thrombosis. Conclusion: The CWA-APTT and CWA-sTF/FIXa can increase the evaluability of HCC including the association with LC and thrombotic complications.","PeriodicalId":10335,"journal":{"name":"Clinical and Applied Thrombosis/Hemostasis","volume":"56 1","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140590037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and Safety of Long-Term Dual Antiplatelet Therapy: A Systematic Review and Meta-Analysis 长期双联抗血小板疗法的有效性和安全性：系统回顾与元分析

IF 2.9 4区医学

Clinical and Applied Thrombosis/Hemostasis Pub Date : 2024-04-04 DOI: 10.1177/10760296241244772

Xiaoming Zhang, Da Zhou, Siying Song, Xiangqian Huang, Yuchuan Ding, Ran Meng

{"title":"Efficacy and Safety of Long-Term Dual Antiplatelet Therapy: A Systematic Review and Meta-Analysis","authors":"Xiaoming Zhang, Da Zhou, Siying Song, Xiangqian Huang, Yuchuan Ding, Ran Meng","doi":"10.1177/10760296241244772","DOIUrl":"https://doi.org/10.1177/10760296241244772","url":null,"abstract":"BackgroundDual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is a standard therapy in patients with ischemic vascular diseases (IVD) including coronary artery, cerebrovascular and peripheral arterial diseases, although the optimal duration of this treatment is still debated. Previous meta-analyses reported conflicting results about the effects of long-term and short-term as well as non-DAPT use in various clinical settings. Herein, we conducted a comprehensive meta-analysis to assess the efficacy and safety of different durations of DAPT.MethodsWe reviewed relevant articles and references from database, which were published prior to April 2023. Data from prospective studies were processed using RevMan5.0 software, provided by Cochrane Collaboration and transformed using relevant formulas. The inclusion criteria involved randomization to long-term versus short-term or no DAPT; the endpoints included at least one of total or cardiovascular (CV) mortalities, IVD recurrence, and bleeding.ResultsA total of 34 randomized studies involving 141 455 patients were finally included. In comparison with no or short-term DAPT, long-term DAPT reduced MI and stroke, but did not reduce the total and CV mortalities. Meanwhile, bleeding events were increased, even though intracranial and fatal bleedings were not affected. Besides, the reduction of MI and stroke recurrence showed no statistical significance between long-term and short-term DAPT groups.ConclusionLong-term DAPT may not reduce the mortality of IVD besides increasing bleeding events, although reduced the incidences of MI and stroke early recurrence to a certain extent and did not increase the risk of fatal intracranial bleeding.","PeriodicalId":10335,"journal":{"name":"Clinical and Applied Thrombosis/Hemostasis","volume":"102 1","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140590133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

International Normalized Ratio Predicts Recurrence and Bleeding in Patients With Acute Venous Thromboembolism Who Undergo Direct Oral Anticoagulants 国际标准化比率可预测接受直接口服抗凝药物治疗的急性静脉血栓栓塞症患者的复发和出血情况

IF 2.9 4区医学

Clinical and Applied Thrombosis/Hemostasis Pub Date : 2024-04-03 DOI: 10.1177/10760296241246004

Yunfeng Zhao, Yi Cheng, Yong Luo, Qihuan Yao, Jianmin Qu, Jinyuan Sun, Song Liu, Mei Xu, Wei Xiong

{"title":"International Normalized Ratio Predicts Recurrence and Bleeding in Patients With Acute Venous Thromboembolism Who Undergo Direct Oral Anticoagulants","authors":"Yunfeng Zhao, Yi Cheng, Yong Luo, Qihuan Yao, Jianmin Qu, Jinyuan Sun, Song Liu, Mei Xu, Wei Xiong","doi":"10.1177/10760296241246004","DOIUrl":"https://doi.org/10.1177/10760296241246004","url":null,"abstract":"Prothrombin time/international normalized ratio (PT/INR) is related to both antithrombotic effect and risk of bleeding. Its role in the prediction of venous thromboembolism (VTE) recurrence and bleeding for patients with acute VTE who undergo direct oral anticoagulants (DOACs) treatment is unclear, despite previous studies revealed some association between them. The predictive efficiency of INR for VTE recurrence and bleeding were analyzed in a retrospective cohort with VTE patients who underwent DOACs treatment. Then its predictive efficiency for VTE recurrence and bleeding were validated in a prospective cohort with the acquired cutoffs range, and compared with anti-Xa level, DASH and VTE-BLEED scores. In the retrospective cohort ( n = 1083), the sensitivity and specificity of INR for the prediction of VTE recurrence were 79.4% and 92.8%, respectively. The area under the curve (AUC) was 0.881 (0.803-0.960)( P = .025). The cutoff value of INR was 0.9. The sensitivity and specificity of INR for the prediction of bleeding were 85.7% and 77.9%, respectively. The AUC was 0.876 (0.786-0.967)( P < .001). The cutoff value of INR was 2.1. In the prospective cohort ( n = 202), the calibration showed that there were 4 (50%) patients with VTE recurrence, 156 (97.5%) patients with non-recurrence and bleeding (non-R&B), and 20 (58.8%) patients with bleeding in the low (INR < 0.9)( n = 8), intermediate (0.9 ≤ INR ≤ 2.1)( n = 160), and high (INR > 2.1)( n = 34) groups, respectively. The baseline PT/INR value at the initiation of DOACs treatment is an independent predictor for VTE recurrence and bleeding in patients with acute VTE who undergo DOACs treatment.","PeriodicalId":10335,"journal":{"name":"Clinical and Applied Thrombosis/Hemostasis","volume":"7 1","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140590129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biomarkers Profile in Provoked Versus Unprovoked Deep Venous Thrombosis 诱发与非诱发深静脉血栓的生物标记物概况

IF 2.9 4区医学

Clinical and Applied Thrombosis/Hemostasis Pub Date : 2024-04-03 DOI: 10.1177/10760296241238211

Isabela Rodrigues Tavares, Roberto Augusto Caffaro, Maria Fernanda Portugal, Camilla Moreira Ribeiro, Viviane Santana da Silva, Emily Krupa, Srdjan Nikolovski, Karen Falcão de Britto, Ana Cláudia Gomes Pereira Petisco, Maria Cristina Miranda, Sandra Gomes de Souza Santos, Marcela da Silva Dourado, Paula Veloso Siqueira, Fakiha Siddiqui, Jawed Fareed, Eduardo Ramacciotti

{"title":"Biomarkers Profile in Provoked Versus Unprovoked Deep Venous Thrombosis","authors":"Isabela Rodrigues Tavares, Roberto Augusto Caffaro, Maria Fernanda Portugal, Camilla Moreira Ribeiro, Viviane Santana da Silva, Emily Krupa, Srdjan Nikolovski, Karen Falcão de Britto, Ana Cláudia Gomes Pereira Petisco, Maria Cristina Miranda, Sandra Gomes de Souza Santos, Marcela da Silva Dourado, Paula Veloso Siqueira, Fakiha Siddiqui, Jawed Fareed, Eduardo Ramacciotti","doi":"10.1177/10760296241238211","DOIUrl":"https://doi.org/10.1177/10760296241238211","url":null,"abstract":"Venous thromboembolism (VTE), including deep venous thrombosis (DVT) and pulmonary embolism (PE), represents a substantial healthcare challenge. Provoked and unprovoked DVT cases carry distinct risks and treatment considerations. Recognizing the limitations of this classification, molecular markers may enhance diagnostic precision and guide anticoagulation therapy duration relying on patient history and risk factors. This preliminary, open-label, prospective cohort study was conducted including 15 patients (10 provoked DVT and 5 unprovoked DVT) and a control group of healthy plasmatic subjects. Plasma levels of 9 biomarkers were measured at diagnosis (baseline, day 0, and D0) and after 30 days (day 30-D30). Patient demographics, clinical data, and biomarker concentrations were analyzed. Serum concentrations of D-dimer, von Willebrand factor, C-reactive protein, and Anti-Xa were elevated in DVT groups at D0 compared to controls. No significant differences were observed between the provoked and unprovoked groups on the day of diagnosis and 30 days later. Over 30 days, the provoked group exhibited significant biomarker changes related to temporal assessment. No significant differences were noted in the biomarker profile between provoked and unprovoked DVT groups. This study is indicative of the concept of individualized thrombosis assessment and subsequent treatment for VTE. Larger cohorts are warranted to validate these findings and further define the most appropriate use of the molecular markers.","PeriodicalId":10335,"journal":{"name":"Clinical and Applied Thrombosis/Hemostasis","volume":"35 1","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140590050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Super Formula for Soluble C-Type Lectin-Like Receptor 2 × D-Dimer in Patients With Acute Cerebral Infarction. 急性脑梗塞患者可溶性 C 型类凝集素受体 2 × D-二聚体的超级公式。

IF 2.9 4区医学

Clinical and Applied Thrombosis/Hemostasis Pub Date : 2024-01-01 DOI: 10.1177/10760296241232858

Toshitaka Kamon, Hideo Wada, Shotaro Horie, Tomoya Inaba, Karin Okamoto, Katsuya Shiraki, Yuhuko Ichikawa, Minoru Ezaki, Motomu Shimaoka, Akisato Nishigaki, Akihiro Shindo, Hideto Shimpo, Nobuo Ito

{"title":"Super Formula for Soluble C-Type Lectin-Like Receptor 2 × D-Dimer in Patients With Acute Cerebral Infarction.","authors":"Toshitaka Kamon, Hideo Wada, Shotaro Horie, Tomoya Inaba, Karin Okamoto, Katsuya Shiraki, Yuhuko Ichikawa, Minoru Ezaki, Motomu Shimaoka, Akisato Nishigaki, Akihiro Shindo, Hideto Shimpo, Nobuo Ito","doi":"10.1177/10760296241232858","DOIUrl":"10.1177/10760296241232858","url":null,"abstract":"<p><p>Acute cerebral infarction (ACI) includes atherosclerotic and cardiogenic ACI and involves a thrombotic state, requiring antithrombotic treatment. However, the thrombotic state in ACI cannot be evaluated using routine hemostatic examinations. Plasma soluble C-type lectin-like receptor 2 (sCLEC-2) and D-dimer levels were measured in patients with ACI. Plasma sCLEC-2 and D-dimer levels were significantly higher in patients with ACI than in those without it. The sCLEC-2 × D-dimer formula was significantly higher in patients with ACI than in those without it. A receiver operating characteristic curve showed a high sensitivity, area under the curve, and odds for diagnosing ACI in the sCLEC-2 × D-dimer formula. Although the sCLEC-2 and D-dimer levels were useful for the differential diagnosis between cardiogenic and atherosclerotic ACI, the sCLEC-2 × D-dimer formula was not useful. sCLEC2 and D-dimer levels are useful for the diagnosis of ACI and the sCLEC2 × D-dimer formula can enhance the diagnostic ability of ACI, and sCLEC2 and D-dimer levels may be useful for differentiating between atherosclerotic and cardioembolic ACI.</p>","PeriodicalId":10335,"journal":{"name":"Clinical and Applied Thrombosis/Hemostasis","volume":"30 ","pages":"10760296241232858"},"PeriodicalIF":2.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10896059/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139971198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0